CAS: 200064-11-5; 4-(5-Bromo-2-Pyridyl)Morpholine

相似化合物

24255-25-2 1199773-09-5 1259313-58-0

上下游产品

CAS号110-91-8 吗啉 | CAS号624-28-2 2,5-二溴吡啶 | CAS号53939-30-3 5-溴-2-氯吡啶 | CAS号485799-04-0 6-(4-吗啉基)吡啶-3-硼酸频哪醇酯 | CAS号904326-93-8 6-(4-吗啉基)-3-吡啶硼酸 | CAS号454685-29-1 2-(4-吗啉)-5-乙炔吡啶

📜吗啉,2,5-二溴吡啶 反应生成4-(5-溴吡啶-2-基)吗啉
参考文献:鉴定含有吡啶基的哌嗪基-二氟茚衍生物作为针对 Fgfr 突变肿瘤的有效 Fgfr 抑制剂:设计,合成和生物学评价
标题:鉴定含有吡啶基的哌嗪基-二氟茚衍生物作为针对 Fgfr 突变肿瘤的有效 Fgfr 抑制剂:设计,合成和生物学评价
摘要:成纤维细胞生长因子受体 (fgfr) 信号通路在增殖,分化和迁移等细胞过程中起重要作用.在这项研究中,我们强调了带有 (S)-3,3-二氟-1-(4-甲基哌嗪-1-基)-2,3-二氢-1H-茚支架的 Fgfr 抑制剂治疗 Fgfr 突变癌的潜力.通过综合评价鉴定的代表性化合物 (S)-23置于6.4-10.4 Nm 范围内对 Fgfr1 融合蛋白携带,Fgfr2 扩增和 Fgfr2 突变癌细胞系表现出有效的抗增殖活性,对 Fgfr3 易位和突变 Fgfr4 癌细胞系具有非常好的抗增殖活性,以及对 Fgfr1-4 激酶的效力评估.此外,化合物 (S)-23置于mfe-296 异种移植小鼠模型中表现出非常好的药代动力学特性,低药物相互作用的可能性和非常有效的抗肿瘤活性,在 10 Mg/kg 剂量下 Tgi 为 99.1%.这些发现表明,化合物 (S)-23 是 Fgfr 突变肿瘤的潜在治疗剂.
Doi:10.1021/acs.Jmedchem.3C02040

专利信息

专利号:US-2025179012-A1
优先权日:2022-03-04
标 题:Synthesis of sulfur(vi) compounds and reagents for same
发明人：LOPCHUK JUSTIN MATTHEW; SHULTZ ZACHARY
权利人:H LEE MOFFITT CANCER CT & RES
摘要:This disclosure provides reagents and processes for the synthesis of organic compounds, more particularly reagents and processes for the asymmetric synthesis of sulfur (VI) containing organic compounds.

专利号:WO-2023168108-A2
优先权日:2022-03-04
标 题 :Synthesis of sulfur(vi) compounds and reagents for same

专利号:US-2007275968-A1
优先权日:2004-09-07
标 题 :Substituted Biphenyl Derivative
发明人：KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
权利人:KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
摘要:The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: n nwherein n R 1 represents a C 6 -C 10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C 1 -C 6 alkyl)amino group, a di-(C 1 -C 6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C 1 -C 6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R 2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R 3 represents a C 1 -C 6 alkyl group, and so on; and R 4 represents a C 1 -C 6 alkyl group, and so on.